Should I buy or sell Enfusion stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ENFN shares. View ENFN analyst ratings or view top-rated stocks .

What is Enfusion's stock price target for 2024?

6 brokers have issued twelve-month price targets for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 2.5% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts .

How have ENFN shares performed in 2024?

Enfusion's stock was trading at $9.70 on January 1st, 2024. Since then, ENFN stock has decreased by 6.1% and is now trading at $9.1050. View the best growth stocks for 2024 here .

Are investors shorting Enfusion?

Enfusion saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decrease of 25.2% from the March 15th total of 3,020,000 shares. Based on an average trading volume of 409,100 shares, the days-to-cover ratio is currently 5.5 days. Approximately 4.9% of the company's stock are sold short. View Enfusion's Short Interest .

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ENFN earnings forecast .

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) issued its quarterly earnings data on Tuesday, March, 12th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by $0.02. The firm had revenue of $46.49 million for the quarter, compared to analyst estimates of $45.56 million. Enfusion had a trailing twelve-month return on equity of 10.30% and a net margin of 3.45%.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million.

When did Enfusion IPO?

Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (0.62%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo , Stephen Malherbe, Tarek Hammoud and Valeria Gutowski. View institutional ownership trends .

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:ENFN

Enfusion (ENFN) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free ENFN Stock Alerts

$9.17

+0.06 (+0.66%)

(As of 10:36 AM ET)

Compare

Today's Range: $9.07
▼
$9.17
50-Day Range: $8.18
▼
$9.66
52-Week Range: $7.37
▼
$11.56

Volume: 18,731 shs
Average Volume: 384,616 shs
Market Capitalization: $1.17 billion

P/E Ratio: 114.64
Dividend Yield: N/A
Price Target: $9.33

Get Enfusion alerts:

Enfusion MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.67 Rating Score
Upside/Downside: 2.5% Upside
$9.33 Price Target
Short Interest: Healthy
4.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1,179 Sold Last Quarter
Proj. Earnings Growth: 142.86%
From $0.07 to $0.17 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Computer And Technology Sector

353rd out of 583 stocks

Prepackaged Software Industry

133rd out of 201 stocks

0.8

Analyst's Opinion

Consensus Rating
Enfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.
Amount of Analyst Coverage
Enfusion has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.93% of the float of Enfusion has been sold short.
Short Interest Ratio / Days to Cover
Enfusion has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in Enfusion has recently decreased by 25.17%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Enfusion does not currently pay a dividend.
Dividend Growth
Enfusion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENFN.

2.6

News and Social Media Coverage

News Sentiment
Enfusion has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Enfusion this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,179.00 in company stock.
Percentage Held by Insiders
39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Enfusion are expected to grow by 142.86% in the coming year, from $0.07 to $0.17 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enfusion is 113.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.92.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enfusion is 113.83, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 221.93.
Price to Earnings Growth Ratio
Enfusion has a PEG Ratio of 2.71. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Enfusion has a P/B Ratio of 14.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Enfusion Stock (NYSE:ENFN)

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENFN Stock News Headlines

April 18, 2024 | businesswire.com

Enfusion Announces Date of First Quarter 2024 Results

April 17, 2024 | morningstar.com

Enfusion Inc Class A

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

April 12, 2024 | americanbankingnews.com

Enfusion, Inc. (NYSE:ENFN) Receives Consensus Rating of "Reduce" from Brokerages

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

April 4, 2024 | msn.com

The 3 Most Undervalued Under-$10 Stocks to Buy in April 2024

April 2, 2024 | finance.yahoo.com

Will Enfusion (ENFN) Grow Revenue And Expand Margins In The Future?

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

April 2, 2024 | businesswire.com

ConnexPay Appoints Ben Peters as Chief Executive Officer

March 27, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

March 22, 2024 | markets.businessinsider.com

Enfusion’s Growth Strategy Met with Sell Rating Amid Market and Strategic Challenges

March 21, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Technology Stocks: GoDaddy (GDDY) and Enfusion (ENFN)

March 20, 2024 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

March 15, 2024 | markets.businessinsider.com

Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024

March 14, 2024 | seekingalpha.com

Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript

March 14, 2024 | finance.yahoo.com

Enfusion, Inc. (NYSE:ENFN) Q4 2023 Earnings Call Transcript

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Copperleaf Tech (OtherCPLFF), Rackspace Technology (RXT) and Enfusion (ENFN)

March 12, 2024 | markets.businessinsider.com

William Blair Reaffirms Their Buy Rating on Enfusion (ENFN)

March 12, 2024 | msn.com

Enfusion reports mixed Q4 results; initiates FY24 outlook

March 12, 2024 | finance.yahoo.com

Enfusion Announces Fourth Quarter 2023 Results and Full Year 2023 Results

March 11, 2024 | benzinga.com

Earnings Outlook For Enfusion

March 6, 2024 | benzinga.com

Major Purchase Alert: Oleg Movchan Invests $120K In Enfusion Stock

February 29, 2024 | msn.com

Goldman Sachs Downgrades Enfusion (ENFN)

February 28, 2024 | msn.com

Enfusion stock retreats after Goldman downgrades to Sell

February 28, 2024 | markets.businessinsider.com

Enfusion Stock Sell Rating: Conservative Revenue Growth and Market Challenges Ahead

See More Headlines

Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Computer and Technology
Industry: Prepackaged software
Sub-Industry: N/A
Current Symbol: NYSE:ENFN
CUSIP: N/A
CIK: 1868912
Web: www.enfusion.com
Phone: 312-253-9800
Fax: N/A
Employees: 1,102
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.33
High Stock Price Target: $11.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +1.8%
Consensus Rating: Reduce
Rating Score (0-4): 1.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.08
Trailing P/E Ratio: 114.64
Forward P/E Ratio: 131.00
P/E Growth: 2.71
Net Income: $6.03 million
Net Margins: 3.45%
Pretax Margin: 6.58%
Return on Equity: 10.30%
Return on Assets: 7.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.44
Quick Ratio: 3.44

Sales & Book Value

Annual Sales: $174.54 million
Price / Sales: 6.73
Cash Flow: $0.14 per share
Price / Cash Flow: 64.53
Book Value: $0.61 per share
Price / Book: 15.03

Miscellaneous

Outstanding Shares: 128,070,000
Free Float: 77,892,000
Market Cap: $1.17 billion
Optionable: Optionable
Beta: 1.00

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Oleg Movchan (Age 49)
CEO & Director
Comp: $876.34k
Mr. Bradley Herring (Age 53)
Chief Financial Officer
Comp: $267.05k
Ms. Bronwen Bastone (Age 51)
Chief People Officer
Comp: $566.25k
Mr. Stephen Malherbe
Managing Partner
Mr. Neal Pawar
Chief Operating Officer
Ms. Valeria Gutowski (Age 42)
Chief Accounting Officer
Mr. Daniel Groman (Age 35)
Chief Technology Officer
Mr. Ignatius Tochukwu Njoku
Head of Investor Relations
Matt Campobasso
General Counsel
Mr. Joseph Defeo
Global Head of Managed Services Production

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENFN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ENFN shares.
View ENFN analyst ratings or view top-rated stocks.
What is Enfusion's stock price target for 2024?: 6 brokers have issued twelve-month price targets for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 2.5% from the stock's current price.
View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts.
How have ENFN shares performed in 2024?: Enfusion's stock was trading at $9.70 on January 1st, 2024. Since then, ENFN stock has decreased by 6.1% and is now trading at $9.1050.
View the best growth stocks for 2024 here.
Are investors shorting Enfusion?: Enfusion saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decrease of 25.2% from the March 15th total of 3,020,000 shares. Based on an average trading volume of 409,100 shares, the days-to-cover ratio is currently 5.5 days. Approximately 4.9% of the company's stock are sold short.
View Enfusion's Short Interest.
When is Enfusion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ENFN earnings forecast.
How were Enfusion's earnings last quarter?: Enfusion, Inc. (NYSE:ENFN) issued its quarterly earnings data on Tuesday, March, 12th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by $0.02. The firm had revenue of $46.49 million for the quarter, compared to analyst estimates of $45.56 million. Enfusion had a trailing twelve-month return on equity of 10.30% and a net margin of 3.45%.

What guidance has Enfusion issued on next quarter's earnings?: Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million.
When did Enfusion IPO?: Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.
Who are Enfusion's major shareholders?: Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (0.62%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski.
View institutional ownership trends.
How do I buy shares of Enfusion?: Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENFN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enfusion (ENFN) Stock Price, News & Analysis

Enfusion MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Enfusion Stock (NYSE:ENFN)

ENFN Stock Price History

ENFN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ENFN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™